Two Sigma Advisers
KLDO

Two Sigma Advisers’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Two Sigma Advisers’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46,000
Closed -$342K – 2774
2021
Q2 		$342K Sell
46,000
-51,100
-53% -$362K ﹤0.01% 2095
2021
Q1 		$787K Buy
+97,100
New +$1.06M ﹤0.01% 1790
2020
Q4 		– Sell
-10,300
Closed -$114K – 2669
2020
Q3 		$114K Buy
+10,300
New +$71.3K ﹤0.01% 2256

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's KLDO Position: Q3 2021 in Review

Two Sigma Advisers sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2021, closing a stake of 46,000 shares — an estimated $342K sold.

Two Sigma Advisers first reported a position in KLDO in Q3 2020 and held it in 3 quarters. The position peaked at $787K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q3 2021.

  • Two Sigma Advisers reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 46,000 Kaleido Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $342K.
  • Two Sigma Advisers first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Two Sigma Advisers's Kaleido Biosciences, Inc. Common Stock position peaked at $787K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2021.

Based on Two Sigma Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.